SCHOTT Pharma AG & Co. KGaA — Cyborg Score 6/10

Strategic Profile

SCHOTT Pharma is a leading provider of drug containment and delivery solutions, specializing in primary packaging for injectable pharmaceuticals, with science-based products such as prefillable glass and polymer syringes, cartridges, vials, ampoules, and innovative systems. With approximately 4,700 employees operating 16 GMP-compliant manufacturing sites across Europe, North and South America, and Asia, the firm holds over 1,000 in-house patents and targets climate neutrality by 2030.

Cyborg Score Rationale

SCHOTT Pharma demonstrates solid fundamentals as a market leader in pharmaceutical primary packaging with consistent revenue growth and global scale. However, recent performance challenges are evident: stock has declined significantly from IPO highs, analyst sentiment shows caution with cautious 2026 guidance, and earnings were down in 2025 despite modest revenue growth.

Top Insights

• Market leadership in high-value pharmaceutical packaging with defensive characteristics due to essential nature of primary drug containment
• Recent stock underperformance (-29.64% YoY) despite solid fundamentals suggests market repricing risk or execution concerns
• Strong IP portfolio with 1,000+ patents and deep R&D capabilities (130+ specialists in Switzerland) position company for innovation-driven growth
• FY2025 revenue €986M (+3% YoY) but earnings declined -2.16%, indicating margin pressure despite absolute growth

Named Competitors

• Glass vials and cartridges — European pharmaceutical packaging company
• Polymer drug delivery systems — US-based specialty pharmaceutical packaging
• Healthcare glass products — Japan-based pharmaceutical glass manufacturer

Recent Developments

• (December 2025) SCHOTT Pharma provided cautious 2026 guidance and updated mid-term targets, with slower growth projected
• (June 2025) CEO Andreas Reisse contract extended and Reinhard Mayer appointed as new CFO
• (August 2025) Q3 2025 results highlighted strategic growth in High Value Solutions segment
• (February 2026) Q1 2026 revenue reached €240M, representing 4.8% year-over-year growth

Open the full interactive SCHOTT Pharma AG & Co. KGaA report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.